Sorry, you need to enable JavaScript to visit this website.

NIMENRIX (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Indications And Clinical Use

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.

Indications And Clinical Use

NIMENRIX is indicated for the active immunization of individuals from 6 weeks to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

What's New

No Current Announcements.

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111